Press Releases

October 25, 2022
MONTREAL and CHARLOTTE, N.C. , Oct. 25, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that data from the Phase 3 RAPID clinical trial of
Displaying 1 - 10 of 19
Print Page
RSS Feeds
Email Alerts
Investor Contact
Search